6 / 6
Page 31
Note:
N o v e m b e r 2 1 - 2 2 , 2 0 1 8 | M a d r i d , S p a i n
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Nephrology 2018
Journal of Clinical Nephrology and Therapeutics
|
Volume 2
NEPHROLOGY AND UROLOGY
International Conference on
J Clin Nephrol Ther 2018, Volume 2
LUMINEX ASSAYS – THE NEW REVOLUTION IN RENAL TRANSPLANTATION
IN INDIA
Mahendra N Mishra
Baptist Christian Hospital, India
Background:
The prevalence of End Stage Renal Disease (ESRD) in India is approximately 151 -232/ million which translates into
220,000 individuals. With approximately 7500 transplants every year only 3.4 % of patients are provided optimal treatment. De-
ceased donor transplant accounts for < 0.5% of all transplants only. No precise data is available regarding the donor profile, but in
a standalone commercial laboratory in India of 705 samples over three-year period, nearly 40% of the donors were unrelated,15%
non- first-degree relatives and 18% spousal.
Methods:
748 pre-transplant and 169 post- transplant samples from prospective recipients were evaluated for HLA- class I and
II donor specific IgG antibodies. Additional tests included pooled bead assay and PRA specification on 52% and 5 % samples of
pre-transplant samples respectively. The laboratory added value to these tests by semi-quantitative grading. Donor profile was
scrutinized.
Results:
Luminex Crossmatch in combination with pooled bead assay was found to be an economical and very useful strategy for
evaluation of sensitization and antibody monitoring in nations with economic constraints. Less than half the donors evaluated were
first degree relatives and deceased donations accounted for less than 0.5 %.
Conclusion:
Luminex based pooled bead assay and crossmatch are valuable and cost-effective for recipient work up and there is
an urgent requirement to promote deceased donor transplant in Indian Subcontinent.